



# MARKET RELEASE

16 March 2015

**SIRTEX MEDICAL LIMITED**

**TRADING HALT**

The securities of Sirtex Medical Limited (Company) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 18 March 2015 or when the announcement is released to the market.

Security Code: SRX

Andrew Kabega  
Senior Adviser, Listings Compliance (Sydney)



Sirtex Medical Ltd  
ABN 35 078 166 122  
Level 33  
101 Miller Street  
North Sydney, 2060  
Phone +61 2 9964 8420  
[www.sirtex.com](http://www.sirtex.com)

16<sup>th</sup> March 2015

Andrew Kabega  
ASX Limited  
Exchange Centre  
20 Bridge Street  
Sydney, NSW, 2000

**BY EMAIL:** [andrew.kabega@asx.com.au](mailto:andrew.kabega@asx.com.au)

Dear Andrew

### **Trading Halt Request**

In accordance with ASX Listing Rule 17.1, Sirtex Medical Limited (**Company**) requests a temporary trading halt in the shares of the Company pending an announcement regarding the Company's SIRFLOX study.

The Company expects to be in a position to issue an announcement regarding the SIRFLOX study before the commencement of normal trading on Wednesday, 18<sup>th</sup> March 2015. The trading halt is requested to be in place until the announcement is made.

The Company is not aware of any reason why the trading halt should not be granted, nor is it aware of any other information necessary to inform the market about the trading halt.

The trading halt is requested to be effected immediately to ensure that the market trades only on a fully informed basis.

Yours sincerely

**Darren Smith**  
**Chief Financial Officer and Company Secretary**  
**Sirtex Medical Limited**